Back to Results
First PageMeta Content
Pharmaceutical sciences / Health / Clinical research / Pharmaceutical industry / Drug safety / FDA Fast Track Development Program / New Drug Application / Expanded access / Clinical trial / Food and Drug Administration / Pharmacology / Medicine


Guidance for Industry Expedited Programs for Serious Conditions – Drugs and Biologics U.S. Department of Health and Human Services
Add to Reading List

Open Document

File Size: 275,80 KB

Share Result on Facebook

Company

A. Manufacturing / D. Companion Diagnostics / /

Country

United States / /

/

Event

FDA Phase / /

/

IndustryTerm

cancer therapy / cancer therapies / diagnostic product / biological drug products / drug products / /

MedicalCondition

rare diseases / severely debilitating diseases / disease / serious disease / serious infections / broader disease / targeted cancer / diseases / each disease / available cancer / illness / infectious disease / common diseases / /

MedicalTreatment

immunosuppressive therapy / cancer therapies / alternative therapies / surgery / cancer therapy / /

Organization

U.S. Department of Health and Human Services / Food and Drug Administration Center for Drug Evaluation and Research / Food and Drug Administration / American Academy of Neurology / office of Communication / Food and Drug Administration Center for Drug Evaluation / U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research / office of Communications Division of Drug Information / Center for Biologics Evaluation and Research / Center for Biologics Evaluation and Research Food and Drug Administration / /

Person

Silver Spring / /

/

Position

candidate for these expedited development and review programs / /

Product

information / New Drug / /

Technology

treating cancer / drug development / /

URL

http /

SocialTag